Announcements Trials
Browse Landscape

Phase

Phase 1/2 2Phase 2 1

Status

Completed 27Terminated 7Recruiting 6Unknown 5Active not recruiting 4Not yet recruiting 3Withdrawn 2

Sponsor Class

INDUSTRY 2OTHER 1

Study Type

Interventional 3

Sponsor

Cancer Type

Thoracic 36Other solid neoplasm 3Gastrointestinal 3CNS 3Dermatologic 1Breast 1

Conditions

Pancreatic Neoplasms 2Neoplasm Metastasis 1Melanoma 1Gastrointestinal Neoplasms 1Esophageal Neoplasms 1Colorectal Neoplasms 1Colonic Neoplasms 1Carcinoma, Non-Small-Cell Lung 1Brain Neoplasms 1

Interventions

Oxaliplatin 84Bevacizumab 67Capecitabine 65Fluorouracil 47Drug Therapy 42tislelizumab 41Gemcitabine 40sintilimab 37Leucovorin 36Irinotecan 33lenvatinib 28Cisplatin 25HMPL-013 24S 1 (combination) 22Immune Checkpoint Inhibitors 22camrelizumab 21irinotecan sucrosofate 20Surgical Procedures, Operative 19Radiotherapy 19Paclitaxel 19130-nm albumin-bound paclitaxel 19apatinib 18toripalimab 17Injections 17Folfox protocol 17pembrolizumab 15Immunotherapy 15Specimen Handling 14Cetuximab 14Radiosurgery 13

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Not yet recruiting × Pemetrexed × Gastrointestinal × Clear all
NCT07594626 2026-05-19

BMS-986504 in Combination With Pemetrexed for the Treatment of Metastatic Solid Tumors With MTAP Deletion

Northwestern University

Phase 1/2 Not yet recruiting
72 enrolled
Gastrointestinal

Colonic Neoplasms, Esophageal Neoplasms, Gastrointestinal Neoplasms, Neoplasm Metastasis, Pancreatic Neoplasms

NCT07551778 2026-04-27

Allogeneic NK Cell Therapy Combined With Standard Maintenance Treatment in Advanced Solid Tumors

BOE Technology Group Co., Ltd.

Phase 1/2 Not yet recruiting
20 enrolled
GastrointestinalThoracic

Carcinoma, Non-Small-Cell Lung, Colorectal Neoplasms

NCT07492680 2026-03-25

A Study of BMS-986504 Monotherapy and in Combination With Other Agents in Participants With Advanced and/or Metastatic Solid Tumors With Homozygous MTAP Deletion (MountainTAP-5)

Bristol-Myers Squibb

Phase 2 Not yet recruiting
260 enrolled
CNSDermatologicGastrointestinal

Brain Neoplasms, Melanoma, Pancreatic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡